News Summary
In Clifton Heights, Pennsylvania, infant KJ Muldoon has made medical history by receiving a customized CRISPR gene-editing therapy for CPS1 deficiency. This rare genetic disorder, affecting protein processing, poses significant health risks, but KJ’s treatment offers new hope. Collaborating professionals developed a personalized therapy aimed at correcting KJ’s unique genetic mutation, showing promising results in liver function and overall growth. This groundbreaking case could change the future of treatments for rare genetic disorders.
Philadelphia – A groundbreaking medical achievement has occurred in Clifton Heights, Pennsylvania, where an infant named KJ Muldoon was successfully treated with a customized CRISPR gene-editing therapy for a rare genetic disorder known as carbamoyl-phosphate synthetase 1 deficiency (CPS1 deficiency). This innovative treatment, which is the first of its kind in medical history, potentially offers new hope for children suffering from severe genetic conditions.
KJ, who was diagnosed with CPS1 deficiency shortly after birth, faced a severe metabolic disorder that affects the body’s ability to process proteins effectively, leading to toxic levels of ammonia in the blood. This rare disease impacts approximately 1 in 1.3 million people and carries a daunting 50% mortality rate among affected infants within their first months. KJ was identified as having the most severe variant of the disorder, necessitating urgent and novel medical intervention.
After recognizing the seriousness of KJ’s condition, medical professionals at the Children’s Hospital of Philadelphia (CHOP) and Penn Medicine collaborated to develop a personalized CRISPR gene-editing therapy specifically tailored to his unique genetic mutation. This therapy aims to correct the underlying genetic defect in KJ’s liver cells, essential for restoring normal urea cycle function.
In February 2025, KJ commenced treatment, receiving injections containing billions of gene-editing CRISPR components directed at his liver cells. Using lipid nanoparticles to ensure efficient delivery, the therapy worked by transporting altered DNA directly to the target liver cells. Over the course of several weeks, KJ received three doses in total, with additional administrations in March and April to enhance the therapeutic effects.
As a result of the innovative CRISPR treatment, KJ’s liver function has shown marked improvements. Healthcare professionals have noted encouraging developments in KJ’s overall growth and milestones, including milestones such as sitting up independently and transitioning to solid foods. These signs of progress are particularly significant given the severity of his condition at the outset.
The successful application of CRISPR therapy not only brings hope for KJ but also represents a critical advancement in personalized medicine. Unlike conventional treatments that may apply universally, this therapy was designed solely for KJ, highlighting its tailored approach. Kiran Musunuru, who leads the Penn Cardiovascular Institute’s Genetic and Epigenetic Origins of Disease Program, has suggested this case could revolutionize treatment protocols for rare disorders diagnosed in infants.
Prior to beginning this untested gene therapy, KJ’s family faced a challenging decision between a high-risk liver transplant and the experimental therapy. The choice for CRISPR was made with the understanding of its potential risks and rewards, paving the way for a potentially life-saving intervention.
As KJ continues to progress, medical experts remain cautiously optimistic about his long-term outlook. Key health indicators, such as ammonia levels and amino acid balances, are being closely monitored to assess the ongoing effectiveness of the treatment. Efforts to refine this groundbreaking process could lead to more general applications of personalized gene-editing therapies for various genetic disorders in the future.
The collaborative development and approval of KJ’s therapy involved multiple research and manufacturing partners, receiving rapid clearance from the Food and Drug Administration (FDA), underscoring the urgency surrounding such severe health conditions. The focus now turns to potential broader applications of CRISPR technology, with researchers eager to create universal solutions for other genetic disorders.
Deeper Dive: News & Info About This Topic
HERE Resources
Breakthrough CRISPR Therapy Treats Rare Genetic Disorder in Child
Philadelphia Zoo Welcomes Hatchlings of Galapagos Tortoises
Additional Resources
- CBS News
- Wikipedia: CRISPR
- NBC News
- Google Search: CRISPR gene therapy
- 6ABC Action News
- Encyclopedia Britannica: Gene Editing
- Time
- Google News: Effects of CRISPR in babies
- Endpoints News
- Google Scholar: CRISPR gene therapy
- Wired
